Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1049 | 1299 | 1164 | 868 | 1283 | 1429 |
Fund Return | 4.88% | 29.88% | 16.35% | -4.6% | 5.11% | 3.64% |
Place in category | 9 | 51 | 27 | 73 | 65 | 59 |
% in Category | 2 | 20 | 11 | 43 | 41 | 66 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Franklin Technology Fund I acc USD | 1.07B | 11.94 | 4.61 | 17.28 | ||
Franklin Technology Fund Z acc USD | 24.72M | 11.88 | 4.25 | 16.85 | ||
Franklin Technology Fund A acc USD | 4.48B | 3.78 | 2.11 | 16.19 | ||
Franklin Technology Fund C acc USD | 179.22M | 3.74 | 1.52 | 15.52 | ||
Franklin Technology Fund N acc USD | 329.84M | 3.70 | 1.34 | 15.32 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Pictet Biotech PUSD | 1.37B | -18.50 | 5.47 | 7.18 | ||
Pictet Biotech R USD | 1.37B | -18.92 | 4.74 | 6.44 | ||
Equities L Biotechnology Class I US | 1.44B | 2.72 | 2.18 | 7.26 | ||
Equities L Biotechnology Class R US | 1.44B | 2.99 | 2.98 | 7.71 | ||
Pictet Biotech I USD | 1.37B | 1.14 | -2.61 | 6.56 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Amgen | US0311621009 | 8.72 | 273.54 | +0.60% | |
Regeneron Pharma | US75886F1075 | 6.96 | 907.32 | +0.80% | |
Vertex | US92532F1003 | 6.08 | 404.91 | +1.25% | |
Ascendis Pharma AS | US04351P1012 | 3.86 | 144.83 | +1.92% | |
Gilead | US3755581036 | 3.68 | 67.03 | +0.12% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Neutral | Buy |
Technical Indicators | Strong Sell | Strong Sell | Strong Buy |
Summary | Strong Sell | Sell | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review